THENA Capital
VC Fund
London, United Kingdom
THENA Capital is a venture capital firm investing in early-stage MedTech startups with a focus on women's health and digital care.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries THENA Capital invests in
Stages THENA Capital invests in
Countries THENA Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Pamela Walker
|
|||
Tatum Getty
|
|||
Investment Focus
Industry
- Medical 1 (33%)
- Hospital 1 (33%)
- Wellness 1 (33%)
- Health Care 1 (33%)
- Biotechnology 1 (33%)
Stage
- Seed 2 (67%)
- Venture - Series Unknown 1 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Jason Foster
Venture Partner
|
Venture Partner | Total investments: 3 | Find email | |
|
Pamela Walker
Founding General Partner
|
Founding General Partner | Total investments: 3 | Find email | |
|
Tatum Getty
Founding General Partner
|
Founding General Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Zonova
|
Zonova has developed an antimicrobial additive technology that integrates directly into the polymers used in medical device manufacture, designed to help prevent healthcare-associated infections, a problem affecting roughly 1 in 10 hospital patients worldwide (WHO, 2011). Our patented Z-ROS® chemistry is a non-leaching antimicrobial additive basedon reactive-oxygen-species generation at the polymer surface. It does not use actives, antibiotics or biocides.Z-ROS® is in development for high infection-risk device categories including vascular access devices, orthopaedic implants, urology (connectors, valves, catheters), endotracheal tubes, and pelvic health devices. The intended commercial model is licensing to medical device manufacturers, with masterbatch supply through a contracted compounder. | $2.8M / Seed / May 26, 2026 | |
Salient Bio
|
Salient Bio is building non-invasive diagnostic tests that address difficult-to-identify medical conditions, such as Crohn’s Disease and Ulcerative Colitis. For this we use a combination of microbiome metagenomics and machine learning, which we couple with classical diagnostic approaches. We currently focus on testing human gut, oral, and vaginalmicrobiomes, for which we have built comprehensive bioinformatic analysis options. Our ISO17025-certified lab portfolio also includes a range of classical blood and stool diagnostic tests which we offer alongside our microbiome testing service for our revenue generating proposition. | $3.2M / Seed / Sep 03, 2025 | |
Bloom43
|
Bloom43 uses supraphysiological preconditioning to assist patients prepare and safeguard their bodies before surgery. Bloom43 uses unique technology to give preconditioning therapy, preventing surgical problems. | $4.5M / Venture - Series Unknown / Jul 08, 2025 |
Co-Investors
Angel Academe
1 deal together
Animal Health Angels
1 deal together
The Conduit EIS Impact Fund
1 deal together
Sie Ventures
1 deal together
TCP Health Ventures
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does THENA Capital invest in?
THENA Capital invests primarily in Medical, Hospital and Wellness startups, most often at Seed and Venture - Series Unknown stage. Most of the 3 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact THENA Capital?
Public channels for THENA Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at THENA Capital?
The team at THENA Capital includes Jason Foster (Venture Partner), Pamela Walker (Founding General Partner) and Tatum Getty (Founding General Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
